Recent advances in the treatment of laryngeal and hypopharyngeal carcinoma;Aktuelle Therapieoptionen bei Larynx-und Hypopharynxkarzinomen

HNO

Volumn 60, Issue 1, 2012, Pages 6-18

  Eckel, H E ^a  

^a GENERAL HOSPITAL KLAGENFURT   (Austria)

Author keywords

Laryngeal carcinoma; Quality of life; Radiotherapy; Side effects; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CHEMORADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; EAR NOSE THROAT SURGERY; HUMAN; HYPOPHARYNX TUMOR; LARYNX TUMOR; METHODOLOGY; PATIENT SELECTION;

ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; HUMANS; HYPOPHARYNGEAL NEOPLASMS; LARYNGEAL NEOPLASMS; OTORHINOLARYNGOLOGIC SURGICAL PROCEDURES; PATIENT SELECTION; RADIOTHERAPY, CONFORMAL;

EID: 84856352677     PISSN: 00176192     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00106-011-2422-9     Document Type: Article

References (73)

1. Akman FC, Dag N, Ataman OU et al (2008) The impact of treatment center on the outcome of patients with laryngeal cancer treated with surgery and radiotherapy. Eur Arch Otorhinolaryngol 265: 1245-1255.
2. Ambrosch P, Fazel A (2011) Funktionserhaltende Therapie des Kehlkopf- und des Hypopharynxkarzinoms. Laryngorhinootologie 90(Suppl 1): S83-S109.
3. Argiris A, Heron DE, Smith RP et al (2010) Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol 28: 5294-5300.
4. Argiris A, Karamouzis MV, Raben D et al (2008) Head and neck cancer. Lancet 371: 1695-1709.
5. Bernier J, Domenge C, Ozsahin M et al (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350: 1945-1952.
6. Birchall M, Bailey D, King P (2004) Effect of process standards on survival of patients with head and neck cancer in the south and west of England. Br J Cancer 91: 1477-1481.
7. Birkmeyer JD, Sun Y, Wong SL et al (2007) Hospital volume and late survival after cancer surgery. Ann Surg 245: 777-783.
8. Bootz F (2000) Leitlinien der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie. Onkologie des Kopf-Hals-Bereiches. HNO 48: 104-118.
9. Carvalho AL, Nishimoto IN, Califano JA et al (2005) Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 114: 806-816.
10. Chen AY, Fedewa S, Pavluck A et al (2010) Improved survival is associated with treatment at high-volume teaching facilities for patients with advanced stage laryngeal cancer. Cancer 116(20): 4744-4752.
11. Chen AY, Halpern M (2007) Factors predictive of survival in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg 133: 1270-1276.
12. Chera BS, Amdur RJ, Morris CG et al (2010) T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 78: 461-466.
13. Cohen SM, Garrett CG, Dupont WD et al (2006) Voice-related quality of life in T1 glottic cancer: irradiation versus endoscopic excision. Ann Otol Rhinol Laryngol 115: 581-586.
14. Cooper JS, Pajak Tf, Forastiere Aa et al (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350: 1937-1944.
15. Cooper JS, Porter K, Mallin K et al (2009) National Cancer Database report on cancer of the head and neck: 10-year update. Head Neck 31: 748-758.
16. Cosetti M, Yu GP, Schantz SP (2008) Five-year survival rates and time trends of laryngeal cancer in the US population. Arch Otolaryngol Head Neck Surg 134: 370-379.
17. Damm M, Sittel C, Streppel M et al (2000) Transoral CO2 laser for surgical management of glottic carcinoma in situ. Laryngoscope 110: 1215-1221.
18. Dietz A, Boehm A, Mozet C et al (2008) Current aspects of targeted therapy in head and neck tumors. Eur Arch Otorhinolaryngol 265 (Suppl 1): S3-S12.
19. Dietz A, Rudat V, Dreyhaupt J et al. (2009) Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial). Eur Arch Otorhinolaryngol 266: 1291-1300.
20. Eckel HE, Schröder U, Jungehülsing M et al (2008) Indikationen zur chirurgischen Therapie von Larynx- und Hypopharynxkarzinomen. Wien Med Wochenschr 158: 255-263.
21. Eckel HE, Staar S, Volling P et al (2001) Surgical treatment for hypopharynx carcinoma: feasibility, mortality, and results. Otolaryngol Head Neck Surg 124: 561-569.
22. Forastiere A, Weber R, Ang K (2008) Treatment of head and neck cancer. N Engl J Med 358: 1076; author reply 1077-1078.
23. Forastiere AA (2010) Larynx preservation and survival trends: should there be concern? Head Neck 32: 14-17.
24. Forastiere AA, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349: 2091-2098.
25. Fu KK, Pajak TF, Trotti A et al (2000) A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48: 7-16.
26. Garden AS, Kies MS, Weber RS (2010) To TORS or not to TORS: but is that the question? Comment on "transoral robotic surgery for advanced oropharyngeal carcinoma". Arch Otolaryngol Head Neck Surg 136: 1085-1087.
27. Genden EM, Ferlito A, Rinaldo A et al (2008) Recent changes in the treatment of patients with advanced laryngeal cancer. Head Neck 30: 103-110.
28. Gosepath J (1972) Die verschiedenen Methoden der Teilresektionen des Kehlkopfes. HNO 20: 227-240.
29. Gussenbauer C (1874) Über die erste durch Th. Billroth am Menschen ausgeführte Kehlkopfexstirpation und die Anwendung eines künstlichen Kehlkopfs. Arch Klin Chir 17: 343-356.
30. Hinerman RW, Mendenhall WM, Morris CG et al (2007) T3 and T4 true vocal cord squamous carcinomas treated with external beam irradiation: a single institution's 35-year experience. Am J Clin Oncol 30: 181-185.
31. Hoffman HT, Porter K, Karnell LH et al (2006) Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope 116: 1-13.
32. Holsinger FC, Kies MS, Diaz EM Jr et al (2009) Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol 27: 1976-1982.
33. Iro H, Mantsopoulos K, Zenk J et al (2011) Ergebnisse der transoralen Laserresektion bei T1-2 Karzinomen von Oropharynx, Hypopharynx und Larynx. Laryngorhinootologie 90: 481-485.
34. Karatzanis AD, Psychogios G, Zenk J et al (2009) Comparison among different available surgical approaches in T1 glottic cancer. Laryngoscope 119: 1704-1708.
35. Karatzanis AD, Psychogios G, Zenk J et al (2010) Evaluation of available surgical management options for early supraglottic cancer. Head Neck 32: 1048-1055.
36. Klussmann JP, Gultekin E, Weissenborn SJ et al (2003) Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 162: 747-753.
37. Knecht R (2009) Strahlen-, Chemo- und Targettherapie von Kopf-Hals-Karzinomen: Neue Entwicklungen. HNO 57: 436-445.
38. Kohlfürst S, Markitz M, Raunik W et al (2009) Positronen-Emissionstomografie (PET) und PET/CT bei Kopf-Hals-Tumoren - ein Vorschlag für einen interdisziplinären Konsensus. Laryngorhinootologie 88: 84-90.
39. Kornek G, Selzer E (2009) Targeted therapies in solid tumours: pinpointing the tumour's Achilles heel. Curr Pharm Des 15: 207-242.
40. Kraft M, Glanz H, Von Gerlach S et al (2010) Optische Kohärenztomographie: Stellenwert einer neuen Methode bei der Abklärung unklarer Kehlkopfveränderungen. HNO 58: 472-479.
41. Laccourreye O, Veivers D, Hans S et al (2001) Chemotherapy alone with curative intent in patients with invasive squamous cell carcinoma of the pharyngolarynx classified as T1-T4N0M0 complete clinical responders. Cancer 92: 1504-1511.
42. Lavaf A, Genden EM, Cesaretti JA et al (2008) Adjuvant radiotherapy improves overall survival for patients with lymph node-positive head and neck squamous cell carcinoma. Cancer 112: 535-543.
43. Lefebvre JL, Chevalier D, Luboinski B et al (1996) Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88: 890-899.
44. Leon X, Martinez V, Lopez M et al (2010) Risk of third and fourth tumors in patients with head and neck cancer. Head Neck 32: 1467-1472.
45. Mahler V, Boysen M, Brondbo K (2010) Radiotherapy or CO(2) laser surgery as treatment of T(1a) glottic carcinoma? Eur Arch Otorhinolaryngol 267: 743-750.
46. Martin A, Jackel MC, Christiansen H et al (2008) Organ preserving transoral laser microsurgery for cancer of the hypopharynx. Laryngoscope 118: 398-402.
47. Mendenhall WM, Amdur RJ, Morris CG et al (2001) T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J Clin Oncol 19: 4029-4036.
48. Nguyen NP, Moltz CC, Frank C et al (2004) Dysphagia following chemoradiation for locally advanced head and neck cancer. Ann Oncol 15: 383-388.
49. Olsen KD (2010) Reexamining the treatment of advanced laryngeal cancer. Head Neck 32: 1-7.
50. Peretti G, Piazza C, Ansarin M et al (2010) Transoral CO2 laser microsurgery for Tis-T3 supraglottic squamous cell carcinomas. Eur Arch Otorhinolaryngol 267: 1735-1742.
51. Pignon JP, Bourhis J, Domenge C et al (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC collaborative group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 355: 949-955.
52. Pignon JP, Le Maitre A, Maillard E et al (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17, 346 patients. Radiother Oncol 92: 4-14.
53. Piquet JJ (1976) Functional laryngectomy (cricohyoidopexy). Clin Otolaryngol Allied Sci 1: 7-16.
54. Remacle M, Eckel HE, Antonelli A et al (2000) Endoscopic cordectomy. A proposal for a classification by the Working Committee, European Laryngological Society. Eur Arch Otorhinolaryngol 257: 227-231.
55. Remacle M, Hantzakos A, Eckel H et al (2009) Endoscopic supraglottic laryngectomy: a proposal for a classification by the working committee on nomenclature, European Laryngological Society. Eur Arch Otorhinolaryngol 266: 993-998.
56. Remacle M, van Haverbeke C, Eckel H et al (2007) Proposal for revision of the European Laryngological Society classification of endoscopic cordectomies. Eur Arch Otorhinolaryngol 264: 499-504.
57. Rigual NR, Thankappan K, Cooper M et al (2009) Photodynamic therapy for head and neck dysplasia and cancer. Arch Otolaryngol Head Neck Surg 135: 784-788.
58. Rudat V, Eckel H, Volling P et al (2008) Long-term results of a prospective multicenter phase II study to preserve the larynx function using concomitant boost radiochemotherapy with Carboplatin. Radiother Oncol 89(1): 33-37.
59. Rudert H (1991) Larynx- und Hypopharynxkarzinome - Endoskopische Chirurgie mit dem Laser: Möglichkeiten und Grenzen. Arch Otorhinolaryngol Suppl 1: 3-18.
60. Sadri M, Mcmahon J, Parker A (2006) Management of laryngeal dysplasia: a review. Eur Arch Otorhinolaryngol 263: 843-852.
61. Schrijvers Ml, van Riel El, Langendijk JA et al (2009) Higher laryngeal preservation rate after CO2 laser surgery compared with radiotherapy in T1a glottic laryngeal carcinoma. Head Neck 31: 759-764.
62. Schröder U (2007) Aktueller Stellenwert der offenen Larynxteilresektion unter besonderer Berücksichtigung der suprakrikoidalen Teilresektionen. Laryngorhinootologie 86: 490-499.
63. Schuster M, Toy H, Lohscheller J et al (2005) Lebensqualität und Stimmbeeinträchtigung Laryngektomierter mit Stimmventilprothesen. Laryngorhinootologie 84: 101-107.
64. Selzer E, Liederer S, Lemaire C et al (2011) Incidence of dermatitis in head and neck cancer patients treated with primary radiotherapy and cetuximab. Strahlenther Onkol 187: 373-377.
65. Steiner W (1994) Therapie des Hypopharynxkarzinoms. Teil III: Das Konzept der minimal invasiven Therapie von Karzinomen des oberen Aerodigestivtrakts unter besonderer Berücksichtigung des Hypopharynxkarzinoms und der transoralen Lasermikrochirurgie. HNO 42: 104-112.
66. Tateya I, Hirano S, Kojima H et al (2006) Hyperfractionated radiotherapy for T2 glottic cancer for preservation of the larynx. Eur Arch Otorhinolaryngol 263: 144-148.
67. Thurnher D, Erovic BM, Frommlet F et al (2008) Challenging a dogma-surgery yields superior long-term results for T1a squamous cell carcinoma of the glottic larynx compared to radiotherapy. Eur J Surg Oncol 34: 692-698.
68. Vermorken JB, Trigo J, Hitt R et al (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25: 2171-2177.
69. Vilaseca I, Bernal-Sprekelsen M, Luis Blanch J (2010) Transoral laser microsurgery for T3 laryngeal tumors: Prognostic factors. Head Neck 32: 929-938.
70. Wolf GT (2010) Reexamining the treatment of advanced laryngeal cancer: the VA laryngeal cancer study revisited. Head Neck 32: 7-14.
71. Wright FC, De Vito C, Langer B et al (2007) Multidisciplinary cancer conferences: a systematic review and development of practice standards. Eur J Cancer 43: 1002-1010.
72. Loughran S, Calder N, MacGregor FB et al (2005) Quality of life and voice following endoscopic resection or radiotherapy for early glottic cancer. Clin Otolaryngol 30: 24-47.
73. Rawlins M (2011) Therapeutics, evidence and decision-making: The basis for decisions about the use of therapeutic interventions. Hodder-Arnold, London.